Increased Neutrophil-Subset Associated With Severity/Mortality In ARDS And COVID19-ARDS Expresses The Dual Endothelin-1/VEGFsignal-Peptide Receptor (DEspR): An Actionable Therapeutic Target

Victoria L. M. Herrera, Allan J. Walkey, Mai Q. Nguyen, Christopher M. Gromisch, Julie Z. Mosaddhegi, Matthew S. Gromisch, Bakr Jundi, Soeren Lukassen, Saskia Carstensen, Ridiane Denis, Anna C. Belkina, Rebecca M. Baron, Mayra Pinilla-Vera, Meike Müller, W. Taylor Kimberly, Joshua N. Goldstein, Irina Lehmann, Angela Shih, Roland Eils, Bruce D. Levy, Nelson Ruiz‐OpazoResearch 2021 · DOI

Introduction

Acute Respiratory Distress Syndrome (ARDS) and subsequent multi-organ failure (MOF) are primary drivers of mortality in intensive care units, a challenge exacerbated by the COVID-19 pandemic. While neutrophils are vital for pathogen defense, their dysregulation in hyperinflammatory states leads to "innocent bystander" tissue injury. This study identifies a specific, pathogenic subset of neutrophils—characterized by the expression of the Dual Endothelin-1/VEGFsignal-Peptide Receptor (DEspR)—that is associated with disease severity and mortality. These "rogue" neutrophils are apoptosis-resistant, contributing to persistent inflammation, but can be targeted for clearance using a humanized anti-DEspR antibody.

Identifying the Pathogenic Neutrophil Subset

The researchers hypothesized that DEspR, a receptor known to promote survival in cancer cells, might also confer apoptosis resistance to a subset of neutrophils in ARDS. Using a combination of flow cytometry, immunofluorescence, and single-cell RNA sequencing (scRNA-seq), they identified circulating DEspR+CD11b+ activated neutrophils (DEspR+actNs) as key players.

DEspR expression on normal human volunteer (NHV) neutrophils.

In clinical cohorts of both classic ARDS and COVID-19 ARDS, the presence of these cells correlated strongly with poor outcomes. Specifically, the number of DEspR+ activated neutrophils showed a strong negative correlation with ICU-free days (Spearman $r = -0.80, P = 0.0002$). Furthermore, high levels of these cells were predictive of lower survival probability.

Mechanisms of Persistent Inflammation

The study revealed that DEspR+ neutrophils in severe COVID-19 patients exhibit an autocrine loop, expressing both the receptor and its ligand, Endothelin-1. This self-sustaining signal likely contributes to their survival. Additionally, these cells are closely linked to NETosis—the release of neutrophil extracellular traps—which can clog microvessels and cause secondary organ damage. Unlike normal neutrophils, this DEspR+ subset resists programmed cell death, allowing them to remain active in the circulation and lungs far longer than necessary.

A Novel Therapeutic Strategy: Inducing Subset-Specific Apoptosis

A critical finding of this research is that the apoptosis resistance of DEspR+ neutrophils can be reversed. The team utilized hu6g8, a humanized anti-DEspR-IgG4 S228P antibody, in ex vivo experiments. Treatment of ARDS patient blood and non-human primate (NHP) neutrophils with hu6g8 successfully induced apoptosis.

Live-cell imaging confirmed that the antibody engages the target and is internalized, triggering the cell's death machinery. This approach offers a significant advantage over broad immunosuppression: it specifically targets the "rogue" subset responsible for tissue damage while potentially leaving the broader immune response intact.

Conclusion and Future Outlook

This study differentiates DEspR+actNs as a targetable neutrophil subset associated with ARDS severity. By identifying a mechanism to "shut down" these hyperinflammatory cells, the researchers have proposed a potential new therapeutic paradigm for severe respiratory failure.

While the results are promising, the authors note that the pilot study's small sample size ($n=30$) necessitates larger clinical trials. Future work will also need to address the in vivo efficacy of hu6g8 and monitor for potential off-target effects, particularly in the kidneys where DEspR is also expressed. Nonetheless, the identification of DEspR as both a biomarker and an actionable target marks a significant step forward in managing critical illness.

Summary updated

Abstract

Abstract Neutrophil-mediated secondary tissue injury underlies acute respiratory distress syndrome (ARDS) and progression to multi-organ-failure (MOF) and death, processes linked to severe COVID19. This ‘innocent bystander’ tissue injury arises in dysregulated hyperinflammatory states from neutrophil functions and neutrophil extracellular traps (NETs) intended to kill pathogens, but injure cells instead, causing MOF. Insufficiency of prior therapeutic approaches suggest need to identify dysregulated neutrophil-subset(s) and induce subset-specific apoptosis critical for neutrophil function-shutdown and clearance. We hypothesized that neutrophils expressing the pro-survival dual endothelin-1/signal peptide receptor, DEspR, are apoptosis-resistant just like DEspR+ cancer cells, hence comprise a consequential pathogenic neutrophil-subset in ARDS and COVID19-ARDS. Here, we report correlation of circulating DEspR+CD11b+ activated neutrophils (DESpR+actNs) and NETosing-neutrophils with severity in ARDS and in COVID19-ARDS, increased DEspR+ neutrophils and monocytes in post-mortem ARDS-patient lung sections, and neutrophil DEspR/ET1 receptor/ligand autocrine loops in severe COVID19. Unlike DEspR[-] neutrophils, ARDS patient DEspR+actNs exhibit apoptosis-resistance, which decreased upon ex vivo treatment with humanized anti-DEspR-IgG4 S228P antibody, hu6g8. Ex vivo live-cell imaging of non-human primate DEspR+actNs showed hu6g8 target-engagement, internalization, and induction of apoptosis. Altogether, data differentiate DEspR+actNs as a targetable neutrophil-subset associated with ARDS and COVID19-ARDS severity, and suggest DEspR-inhibition as a potential therapeutic paradigm. 1-sentence summary: Circulating DEspR+CD11b+ neutrophils and NETosing neutrophils are associated with severity and mortality in ARDS and COVID19-ARDS.
BibTeX
@inproceedings{herrera2021increased,
  author = {Victoria L. M. Herrera and Allan J. Walkey and Mai Q. Nguyen and Christopher M. Gromisch and Julie Z. Mosaddhegi and Matthew S. Gromisch and Bakr Jundi and Soeren Lukassen and Saskia Carstensen and Ridiane Denis and Anna C. Belkina and Rebecca M. Baron and Mayra Pinilla-Vera and Meike Müller and W. Taylor Kimberly and Joshua N. Goldstein and Irina Lehmann and Angela Shih and Roland Eils and Bruce D. Levy and Nelson Ruiz‐Opazo},
  title = {{Increased Neutrophil-Subset Associated With Severity/Mortality In ARDS And COVID19-ARDS Expresses The Dual Endothelin-1/VEGFsignal-Peptide Receptor (DEspR): An Actionable Therapeutic Target}},
  booktitle = {Research},
  year = {2021},
  doi = {10.21203/rs.3.rs-846250/v1},
}
Figure